- |||||||||| Darzalex IV (daratumumab) / J&J, teclistamab (JNJ-64007957) / Genmab, J&J
Preclinical, Journal, PD(L)-1 Biomarker, IO biomarker: Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab. (Pubmed Central) - Feb 7, 2021 JNJ-7957 effectively kills MM cells ex vivo, including those from heavily pretreated MM patients, whereby several components of the immunosuppressive BM microenvironment had only modest effects on its killing capacity. Our findings support the ongoing trial with JNJ-7957 as single agent, and provide the preclinical rationale for evaluating JNJ-7957 in combination with daratumumab in MM.
- |||||||||| Actemra IV (tocilizumab) / Roche, JW Pharma
Journal, IO Biomarker: T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma. (Pubmed Central) - Nov 25, 2020 Cytokine release syndrome is the most common adverse event, which can be adequately managed with tocilizumab or steroids...GPRC5D, CD38 and FcRH5), are also evaluated in early phase clinical trials. Such bispecific antibodies, targeting other antigens, may be given to patients with low baseline BCMA expression, disease with substantial heterogeneity in BCMA expression, following prior BCMA-targeted therapy, or combined with BCMA bispecific antibodies to prevent development of antigen escape.
|